Podocyte is a highly differentiated, polarized epithelial cell that plays an important role in the physiology and pathophysiology of the kidney glomerulus [1] . The basal cell membrane of podocyte gives rise to long primary processes called foot processes or pedicles. The pedicles of neighboring podocytes regularly interdigitate, creating the filtration slits of a constant width of ∼30 to 40 nm that are mainly responsible for the size selectivity of the glomerulus filter [1] . An intact glomerular filtration barrier is an essential part of a functional kidney. Any failure of this complex filtration system leads to proteinuria, which is not only a prognostic clinical parameter but also an important causative factor for progressive loss of renal function [2] [3] [4] . A rapid and reversible retraction and flattening of the foot processes occur due to the detachment of podocyte foot processes from the glomerular basement membranes (GBM) during proteinuria indicating podocyte basement membrane adhesion to be of critical relevance for a functional filter [2] . The molecules that are considered to be important for podocyte-basement membrane adhesion are the podocyte membrane receptors (e.g., integrins [5] and dystroglycans [6] ) and matrix proteins like collagen IV [7] , laminin, entacin, agrin, and perlecan [8] . Among the integrins, it is the a 3 b 1 that is highly expressed in glomerular podocytes in a polarized pattern along the GBM [9, 10] . It binds to collagen, fibronectin, laminin, and entactin/nidogen, present in GBM [11, 12] . In fact, mice deficient in one of the laminin chains that signals through a 3 b 1 integrin have been found to have impaired glomerular development [13] . Ligand binding to a 3 b 1 integrin induces clustering of integrins to form focal adhesions and recruitment of intracellular cytoskeletal proteins. It also leads to intracellular signaling for various other physiologic responses. Podocytes deficient in a 3 b 1 integrin appear unable to assemble mature foot processes, and cytoplasmic projections from the podocyte body are flattened against the GBM [14] . GBM is also found to be fragmented, and along much of its length, a failure of fusion of the epithelial-and endothelialderived components has been detected [14] . The formation of immature capillaries within glomeruli due to the a 3 b 1 integrin-deficient podocyte also suggests a dynamic process during glomerulogenesis where migration of podocytes around the in-growing capillaries, mediated by a 3 b 1 integrin, plays an important role in stimulating capillary branching and maturation of the basement membrane. Therefore, this may play an important role as receptors, transducing signals on contact with the extracellular matrix (ECM), generate specific biologic responses that influence the behavior of both podocytes and endothelial cells within the glomerulus. Until now the detailed molecular mechanisms of the glomerular filtration process were not completely understood, but it is believed that vascular permeability factor/vascular endothelial growth factor (VPF/VEGFA) has a distinct role in this context [15, 16] .
VPF/VEGF-A is a multifunctional cytokine with important roles in both vasculogenesis and angiogenesis [17] [18] [19] [20] [21] [22] [23] . During glomerular development, the podocytes express VPF/VEGF-A whereas its receptors, fetal liver kinase-1 (flk-1) and fms-like tyrosine kinase 1 (flt-1), are found in the endothelial cells [24] . In the mature glomeruli, VPF/VEGF-A is also expressed suggesting it plays a role in maintaining the filtration barrier either through survival, proliferation, and/or differentiation cues to the adjacent specialized endothelia. Very recent evidence also suggests that VPF/VEGF-A secreted from podocytes may act as an autocrine factor on calcium homeostasis and cell survival [25] .
Heterozygous mice at the age of 2 1 / 2 weeks with podocyte specific knockout for VPF/VEGF-A shows endotheliosis and "bloodless glomeruli" that progress to nephrotic syndrome. The end-stage kidney failure is also observed in the same heterozygous mice at 9 to 12 weeks. The podocyte-specific homozygous die at birth or within 18 hours of birth with hydrops, kidney failure, and grossly abnormal glomeruli that lack mature endothelial cells [26] . Additionally, recent data from our laboratory suggest that the proteinuria noted in patients with preclampsia may be due to an excess of circulating soluble VPF/VEGF-A receptor-1 (sFlt-1) [27] .
Moreover, a significant percentage of patients being treated with VPF/VEGF-A signaling inhibitors in clinical cancer trials have been found to have hypertension and proteinuria [28] .
Taken together these data suggest that constitutive expression of VPF/VEGF-A in the glomerular podocytes maintains glomerular endothelial health and provides a barrier against proteinuria during glomerular health. During diseased states such as experimental glomerulonephritis and thrombotic microangiopathy of the rat, VPF/VEGF-A is involved in glomerular capillary repair and healing [29, 30] . Impaired angiogenesis has also been found in the remnant kidney model and correlates with its progression. Kang et al [31] showed that VPF/VEGF-A treatment reduces fibrosis and stabilizes renal function in the remnant kidney model. There are close relationships among VPF/VEGF-A, nitric oxide, endothelin-1, and angiotensin II expression. Interestingly, all of them are involved in a mechanism to regulate glomerular circulation. Also of note, Eremina et al [26] again showed that overexpression of the VPF/VEGF-A isoform in podocytes causes end-stage renal failure due to a collapsing glomerulopathy, which is the pathologic lesion seen in HIV-associated nephropathy [26] . This illustrates a tightly regulated signaling event that controls the expression of VPF/VEGF-A in podocytes and illustrates the need for further molecular and genetic based studies to elucidate the specific, responsible event.
VPF/VEGF-A production is generally regulated by local oxygen concentration. Hypoxia stimulates VPF/VEGF-A production by increasing the VPF/VEGF-A gene transcription [32] and the stability of its mRNA [33] . The increase in transcription occurs through the binding of the transcription factor hypoxia-inducible factor (HIF) to the cis elements in the VPF/VEGF-A promoter [34] . In normoxia, HIF-a subunits are rapidly degraded by the ubiquitin-proteasome pathway, such that the steady-state levels are low and the transcriptional complex cannot form. It was found that the tumor suppressor protein, von Hippel-Lindau gene product (VHL) has a role in this degradation process. The multiprotein complex VHL, elongin b, c, cul-2 has structural homology with E3 type ubiquitin-ligase complex and can indeed ubiquitinate the target protein [35, 36] . In high oxygen concentration HIF-1a is hydroxylated at the proline residues of its oxygen dependent degradation domain. This posttranslational modification of HIF-1a is necessary for its recognition by VHL [37, 38] . However, stabilization of HIF-1a protein levels per se was not sufficient for the transcriptional activation of VPF/VEGF-A. Recent evidence suggests that, in oxygenated cells, HIF-1a is also hydroxylated at an asparagine residue at the COOH-terminal transactivation domain (CAD). As a result, the HIF-1 complex cannot bind to the adaptor protein p300 to execute its transcriptional activity under normoxic conditions [39] [40] [41] . Cellular oxygen concentration is not the only regulator of VPF/VEGF-A synthesis. Some cancer cells can produce high levels of VPF/VEGF-A even in normoxic condition. Clear cell renal carcinoma (RCC) like 786-0, pancreatic carcinoma cell line, ASPC-1, fibrocarcoma cell line, HT1080, ovarian cancer cells, etc., produce elevated levels of VPF/VEGF-A, which are not dependent on hypoxia. In these cells, either oncogenes or growth factors and their receptors induce VPF/VEGF-A synthesis [42] [43] [44] [45] .
VPF/VEGF-A is expressed in the mature podocytes, and its probable function is to maintain the proper filtration barrier in the glomerulus. As glomerulus is not in the hypoxic region in the kidney, the presence of other stimulatory signals is eminent. In this study, we provide preliminary evidence that ECM/podocyte interaction may be important for VPF/VEGF-A up-regulation in podocytes in vitro. The a 3 b 1 integrin, upon interaction with laminin in the GBM, may induce a signaling cascade that increases the association of HIF and p300 in podocytes and, hence, the transcriptional activity of VPF/VEGFA promoter.
METHODS

Stable podocyte cell line
A stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells has been used to understand the signaling events that regulate the expression of VPF/VEGF-A in podocytes [46] . These transformed cells retain numerous specific determinants of visceral epithelial cells. Morphologically these cells show a cobblestone-like appearance similar to parental cells, though they tend to be smaller and grow more densely. The immunologic characteristics of the transformed cells fully correspond with those of parental cells and keep the parental phenotype over successive passages. The presence of cytokeratin, a marker for epithelial differentiation, was identified in both the primary cells and the transformed cells. Two other differentiation markers PHM5, a podocyte specific surface protein and CALLA, a podocyte membrane protein, were again shown to express in this transformed cell. In addition, this transformed cell also expresses WT1, another podocyte specific marker (our unpublished data). The major integrins expressed in these podocytes are a 3 b 1 integrins that are similar to expression in the podocytes of the adult kidney [47] . Like parental cells, this transformed cell has the ability to synthesize fibrinolytic-related compounds with a predominant secretion of free urinary plasminogen activator (u-PA) and to a lesser extent of a plasminogenactivator inhibitor (PAI-1)-tissue plasminogen activator (t-PA) complex. The transformed cells also possess atrial natriuretic factor (ANF) receptors linked to guanylate cyclase confirming its podocyte specificity. The phenotype and differentiation characteristic of transformed cells are same when cultured on matrix proteins although the transformed cells displayed weaker binding to the matrix compare to the parental cells [46, 47] . Cells were grown on plastic or human ECM extracted from the placenta (BD Biosciences, Bedford, MA, USA) or type IV collagen (BD Biosciences) or laminin (BD Biosciences).
RNA preparation and real-time polymerase chain reaction (PCR)
After washing twice with ice-cold phosphate-buffered saline (PBS), podocytes were lysed using lysis buffer from the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The total RNA was extracted according to the RNeasy Mini Kit protocol. We used the Taqman real-time PCR method. The sequence for forward, reverse, and Taqman middle primers for human VPF/VEGF-A and for human 36B4 (housekeeping gene) were taken from the PubMed gene bank and synthesized (Integrated DNA Technology, Coralville, IA, USA). VPF/VEGF-A forward 5 -TAC CTC CAC CAT GCC AAGTG-3 ; VPF/VEGF-A reverse 5 -GAT GAT TCT GCC CTC CTC CTT-3 ; VPF/VEGF-A middle primer 5 -TCC CAG GCT GCA CCC ATG GC -3 ; 36B4 forward 5 -ATG CAG CAG ATC CGC ATG T-3 ; 36B4 reverse 5 -TCA TGG TGT TCT TGC CCA TCA-3 ; and 36B4 middle primer 5 -CAC CAC AGC CTT CCC GCG AA-3 . Each real time PCR reaction was performed using 0.5 lg total RNA, 25 lL reverse transcription (RT)-PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 1.25 lL RNase inhibitor (Applied Biosystems), 50 nmol/L forward primer, 50 nmol/L reverse primer, and 100 nmol/L middle primer. For reverse transcription, a 30-minute period at 48
• C was run before inactivating the reverse transcriptase at 95
• C for 10 minutes. Forty cycles at 95
• C for 15 seconds and 60
• C for 1 minute were performed with an ABI Prism 7700 Sequence Detector (Applied Biosystems). All experiments were carried out three times; and, from each of the three, triplicate readings were taken and the average was calculated. The relative RNA amount was calculated as follows: = CT (VPF/VEGF-A sample) − CT (36B4 sample), = (transfected sample) − (empty vector sample). Relative RNA amount in comparison to the control = 2 − . Average and standard deviation from three experiments were calculated.
Transfection and luciferase assay
Human VPF/VEGF-A promoter (2.6 kb long full length) was cloned into pGL3basic vector (Promega, Madison, WI, USA) to study the VPF/VEGF-A promoter activity using the firefly luciferase as a reporter gene [45] . Podocytes were plated for transfection in a 60 mm tissue culture dish in such a way that cell confluency was 85% to 95% for all experiments. Plasmids were transiently transfected with the Effectene Transfection Kit (Qiagen) according to the manufacturer's protocol. Briefly, 1.0 lg of the VPF/VEGF-A promoter-luciferase construct was re-suspended in EC buffer (150 lL), and 8.0 lL of Enhancer was added and incubated at room temperature for 5 minutes. Effectene (25 lL) was then added, and the whole mixture was incubated for another 10 minutes. Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) (1 mL) was added to the DNA mixtures and then added drop wise to the plate. Thirty hours after transfection cells were washed with PBS, lysed with reporter lysis buffer (Promega) at room temperature for 15 minutes, and followed by luciferase assay. Luciferase activity was measured with a luminometer (MicroLumat LB96P) (Berthold Technologies, Germany) using the luciferase assay kit (Promega). Protein concentration of each lysate was measured to normalize the luciferase reading. Triplicate readings were taken for each experiment and standard deviations were calculated.
Nuclear extract preparation
Podocyte suspension was incubated in a hypotonic buffer [ • C. Finally, the sample was centrifuged at 14,000 rpm for 10 minutes, and the supernatant was collected as nuclear extract.
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed in 0.2 to 0.5 mg of cellular protein from nuclear or whole cell extracts with antibodies (1 lg) directed against HIF-2a, HIF-1a, and p300, and pulled down by protein A agarose beads (Pfizer-Pharmacia, New York, NY, USA). For immunodetection antibodies against HIF-2a, HIF-1a (Novus Biological, Littleton, CO, USA) and p300 (Upstate, Lake Placid, NY, USA) were used.
Enzyme-linked immunosorbent assay (ELISA)
VPF/VEGF-A was measured in the cell culture supernatant using a commercial ELISA kit that measures all the known isoforms of VEGF-A as previously described [27] . This ELISA measures free VPF/VEGF-A concentrations.
Cell adhesion assay
A 96-well microtiter plate was incubated with laminin at 37
• C for 1 hour and then blocked with PBS containing 1% bovine serum albumin (BSA) for another hour Immortalized glomerular podocytes were grown on plastic, human extracellular matrix (ECM), type IV collagen, or on laminin for 48 hours. Real-time polymerase chain reaction (PCR) was performed using primers specific for VPF/VEGF-A with the total RNA isolated from the podocytes cultured on these different matrices. The data represented here are the mean of three independent results.
at the same temperature. Podocytes were trypsinized and suspended in serum-free DMEM at a density of 3× 10 5 cells/mL; then 0.1 mL of the cell suspension was incubated with either antibodies (1:100 dilution, stock concentration 1 mg/mL) against integrin a 3 (Chemicon International, Temecula, CA, USA) and b 1 (BD Pharmingen, San Diego, CA, USA) or with control mouse IgG for 30 minutes. The cell suspensions were then added to each well of the 96-well plate followed by incubation at 37
• C for 3 hours. The attached cells were fixed and stained with a 0.4% crystal violet in methanol (wt/vol) for 30 minutes. After washing with distilled water, the stained cells were monitored under microscope and photographed.
Protein kinase C (PKC) inhibitor assay
Podocytes were incubated with different concentrations (7 nmol/L to 60 nmol/L) of a specific PKC inhibitor, GÖ 6983 (CalBiochem, San Diego, CA, USA). After overnight incubation, nuclear extracts were collected from the cells. Immunoprecipitation reaction with the p300 antibody followed by western blot with either the HIF-1a antibody or the p300 antibody was performed.
RESULTS
Laminin increases the total VPF/VEGF-A mRNA and protein expression in podocytes
Stable podocytes are cultured in a 60 mm tissue culture dish previously coated with either kidney-specific ECM, laminin, or collagen IV. Total mRNA was collected from the confluent cell culture, and real-time PCR was performed with primers specific for VPF/VEGF-A. mRNA level of 36B4 was also measured as an internal control in order to normalize the result. The VPF/VEGF-A mRNA level goes up in the presence of ECM and in the presence of laminin alone but not in the presence of collagen IV (Fig. 1) . This result suggests that the ECM, and particularly the laminin present in the GBM, have the ability to increase the VPF/VEGF-A mRNA level in the absence of hypoxia. The importance of ECM, especially laminin for VPF/VEGF-A expression in podocytes, was also confirmed by ELISA assay, where we found that the protein levels of VPF/VEGF-A were significantly elevated in the conditioned media for podocytes cultured on ECM and laminin (Fig. 2 ).
The integrin a 3 b 1 is important for the regulation of VPF/VEGF-A synthesis in podocytes
Since laminin binds to integrins, we then tested to see if this up-regulation of VPF/VEGF-A synthesis by laminin is mediated through integrin a 3 b 1 . Podocytes (5 × 10 5 cells) were incubated with antibodies against a 3 antibody (Chemicon International, catalogue number MAB 2056) and b 1 (BD Pharmingen) at 37
• C for 30 minutes in suspension, and the whole suspension was plated in 60 mm tissue culture dish previously coated with either kidney-specific ECM or laminin for 48 hours. Cells were also incubated with normal mouse IgG as a control. Total mRNA was collected from confluent cell culture, and real-time PCR was performed with primers specific for VPF/VEGF-A. Antibody treatment inhibits the up-regulation of VPF/VEGF-A mRNA in ECM compared to the control; and, more significantly on laminin (Fig. 3A) . This result demonstrates the importance of laminin in VPF/VEGF-A up-regulation in podocytes and suggests that the signaling event responsible of VPF/VEGF-A synthesis in the podocytes may originate due to the interaction of ECM and, in particular, laminin with integrin a 3 b 1 . Figure 3B represents a control adhesion experiment where we showed that the integrin a 3 and b 1 antibodies indeed could block the association between laminin and a 3 b 1 integrin of podocytes.
Promoter activity of VPF/VEGF-A gene increases in the presence of ECM
VPF/VEGF-A promoter construct (2.6 kb) fused with a luciferase reporter gene was transfected to a stable podocyte cell line cultured in the presence or absence of ECM. After 30 hours of transfection, total luciferase activity, which is proportional to the VPF/VEGF-A promoter activity, was assayed. An increase in promoter activity in the presence of ECM suggests that the increase in transcriptional activity of VPF/VEGF-A promoter activity in the presence of ECM is one of the major reasons for VPF/VEGF-A synthesis in the podocytes (Fig. 4) .
HIF-1a and HIF-2a proteins are expressed in podocytes and remain unchanged when cultured in the presence of ECM
Western blot experiments were performed with the nuclear extracts of the podocytes cultured in the presence or absence of ECM. The specific monoclonal antibodies were used against HIF-1a and HIF-2a proteins (Novus Biological). These experiments ( podocytes under normoxic condition, but the synthesis of these proteins do not increase in the presence of ECM.
The association between HIF-1a and HIF-2a with adaptor protein p300 increases in the presence of ECMs Nuclear extract was collected from the podocytes cultured in the presence or absence of ECM. Immunoprecipitation was performed in 0.2 mg of nuclear extracts with antibodies (1 lg) against p300 and protein A agarose beads, followed by immunodetection with antibodies against HIF-1a and HIF-2a ( Fig. 6A and B ). An increase in association between p300, HIF-1a, and HIF-2a was observed when the podocytes were cultured on ECM. This also explains why the transcription of VPF/VEGF-A increases in the presence of ECM. The same increase in association between HIF-1a and p300 was observed when the cells were plated in the presence of laminin (Fig. 6C) suggesting its involvement in VPF/VEGF-A synthesis in podocytes.
PKC (classical type) acts as an intermediary signaling molecule in this pathway
Recent evidences [48, 49] suggest that PKC can act as a downstream signaling molecule for many integrin- signaling events. In order to know whether PKCs are also important for HIF-1a activation in podocytes, we used specific PKC inhibitors GÖ 6983 (CalBiochem) at different doses in podocytes. The IC 50 values of different PKC isozymes for GÖ 6983 are different and actually help determine the involvement of a specific type of PKC in a signaling pathway. The IC 50 values are as follows: For PKC a and b, it is 7 nmol/L; for PKC d, it is 10 nmol/L; and for PKC f , it is 60 nmol/L. The nuclear extracts of podocytes cultured on laminin were collected after treating them at different concentrations of the inhibitor. Immunoprecipitation was carried out with antibodies against p300 followed by Western blot against HIF-1a antibody. A decrease in the association p300 and HIF-1a was observed at 7 nmol/L dose suggesting the involvement of classical PKCs (PKC a and PKC b in this pathway (Fig. 7 ).
DISCUSSION
We demonstrate in this paper that podocyte expression of VPF/VEGF-A involves a nonhypoxia-mediated pathway that is dependent on podocyte basement membrane interaction. Podocyte basement membrane interaction is important for maintaining the proper filtration barrier of the glomerulus and glomerular epithelial and endothelial health [50] . The major integrin that is expressed in podocytes and interacts with the matrix proteins of GBM is a 3 b 1 integrin [9, 10] . Interestingly, a 1 integrindeficient podocytes appear to remain adherent to the basement membrane along their entire length of contact suggesting that it is not a simple adhesion receptor [14] . It may thus play an important role as receptors transducing signals on contact with the ECM generate specific biologic responses. We hypothesized that GBM and specifically laminin interacts with a 3 b 1 integrin and results in an increased VPF/VEGF-A synthesis. The experimental results discussed here suggested that the VPF/VEGF-A mRNA and protein level were up-regulated in the stable podocyte cell line in the presence of ECM, specifically when cultured on laminin-a major matrix protein in GBM. More important, blocking of a 3 b 1 integrin signaling by incubating the cells with anti-a 3 b 1 integrin antibodies decreased the VPF/VEGF-A mRNA levels compared to controls in the podocytes cultured on laminin. All these results suggested the importance of a 3 b 1 integrin signaling event after its interaction with matrix protein like laminin for the up-regulation of VPF/VEGF-A mRNA. The result presented in Figure 4 for VPF/VEGF-A promoter activity in podocytes cultured in the presence or absence of ECM suggested that an increase in VPF/VEGFA promoter activity might be important due to an increase in the total mRNA level. Finally, we presented evidences that prove that the interaction of the matrix protein with integrins in podocytes increased the association of the transcription factor HIF with its adaptor protein p300 and thus provided a mechanistic explanation of the increase in VPF/VEGF-A transcriptional activity. We also showed that the PKC, especially the classical types, was the intermediate signaling molecule in this pathway. Therefore, in this study experiments were performed to elucidate the stimulatory event and its downstream signaling pathways that regulate VPF/VEGF-A synthesis in the podocyte. However, there are limitations to this study. Since we used transformed podocytes, the results of this study will need to be confirmed using primary human podocyte cultures. We did not study specific isoforms of laminin and other integrin family members that are expressed in podocytes. Finally, in vivo studies to look at expression of VPF/VEGF-A in specific laminin or integrin knockout animals will need to be done before drawing definite conclusions. Nevertheless, this study is among the first to describe a nonhypoxic regulation of VPF/ VEGF-A production during physiologic states. It forms the foundation for more in-depth research studies of this detail-signaling event at the molecular level for VPF/VEGF-A synthesis in podocytes in the future. A thorough knowledge of the molecular pathways of VPF/VEGF-A synthesis in the podocytes is important to gain insight into VPF/VEGF-A related disease progression in glomerulus such as preclampsia, thrombotic microangiopathies, and diabetic nephropathy and is also an important step toward identification of the potential therapeutic targets to circumvent these diseases.
